Microdosing for Depression and Anxiety: What the Clinical Evidence Actually Shows
Placebo-controlled trials of microdosing have consistently failed to show that low doses of psilocybin or LSD outperform placebo for mood, anxiety, or well-being. People taking a...
Psilocybin for Treatment-Resistant Depression: What the Clinical Trials Actually Show
In controlled clinical trials, psilocybin for treatment-resistant depression has produced rapid and often durable symptom reductions after one or two guided sessions, with the largest study...
Psychedelics and Trauma: How These Medicines Work at the Neurological Level
Psychedelics appear to address trauma by temporarily increasing the brain’s capacity to change, opening a window in which fear-based memories become editable rather than fixed. The...
Addiction Psychedelic Therapy: What the Science Says About Breaking the Cycle
Early clinical research on addiction and psychedelic therapy is genuinely promising, with controlled trials showing meaningful reductions in heavy drinking and high abstinence rates in tobacco...
PTSD Psychedelic Therapy: A Science-Based Overview
Among psychedelic approaches to PTSD, MDMA-assisted therapy has the strongest evidence, with two Phase 3 trials showing large symptom reductions, though the FDA declined to approve...
MDMA Therapy 2026 Update: Where Things Stand After the FDA Rejection
The FDA rejected Lykos Therapeutics’ application for MDMA-assisted therapy for PTSD in August 2024, and as of mid-2026 that decision stands. MDMA remains a Schedule I...
Microdosing Protocols in 2026: Fadiman, Stamets, and the Clinical Data
The two most widely followed microdosing protocols are the Fadiman protocol (one day on, two days off) and the Stamets Stack (four or five days on,...
Psilocybin Eating Disorder Treatment: Early Evidence and Cautions
Psilocybin eating disorder treatment is an emerging area of clinical research, with early trials in anorexia nervosa showing that the compound is well-tolerated and may help...
Psilocybin and the Aging Brain: What the Research Shows So Far
Research into psilocybin aging effects is accelerating, with preclinical studies pointing to neuroplasticity promotion, reduced neuroinflammation, and improvements in longevity biomarkers. The findings are genuinely interesting,...
How to Talk to Your Doctor About Psychedelic Therapy
Talking to your doctor about psychedelic therapy is one of the most common points where people get stuck. This guide walks you through how to frame...
Ready to take the next step?
Start with a complimentary conversation, or take the two-minute self-evaluation to see if this is your moment.